AstraZeneca PLC AZN.L
Composite 57/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 22/100 — a strong mark against it.
Quality ranks 77/100 — a strong point in its favour. Growth ranks 74/100 — a moderate point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Momentum ranks 22/100 — a strong mark against it. Valuation ranks 43/100 — a slight mark against it.
What the company does AstraZeneca PLC (AZN.L) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines across oncology, cardiovascular, renal/metabolism, respiratory & immunology, vaccines, and rare diseases.
Key financials Strong profitability with ROE 23.5%, ROA 8.5%, and ROCE 18.0%. Margins: gross 81.5%, operating 27.9%, net 17.2%. Revenue growth 12.5%, EPS growth 5.3%. Debt/Equity 0.64, net debt/EBITDA 1.38, interest coverage 8.34. Dividend yield 0.0%, payout 47.4%.
Stock health Quality pillar score 76.9 signals robust fundamentals. Piotroski F-Score 8/9 and Altman Z 2.85 indicate financial strength. Valuation metrics: P/E 25.83 (fwd 16.37), PEG 1.33, EV/EBITDA 14.29, P/B 5.53, FCF yield 2.5%.
Price vs fair value The stock trades at a discount to both our fair-value estimate and analyst target. - Trading at a discount of 5.30% versus fair-value estimate 13829.35 (Sideravia). - Trading at a discount of 19.56% versus 12-month target 15702.69 (analyst count 22.0). - Recent sector decline and mixed pipeline data may weigh on sentiment (MT Newswires, Simply Wall St.).
Looking forward Forward P/E of 16.37 and PEG of 0.28 suggest undemanding valuation versus growth. Key catalysts include oncology portfolio expansion and respiratory franchise performance. Execution risks remain tied to pipeline progress and regulatory outcomes.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.